370 related articles for article (PubMed ID: 20041839)
21. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T
Curr Drug Discov Technol; 2006 Mar; 3(1):83-8. PubMed ID: 16712466
[TBL] [Abstract][Full Text] [Related]
22. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.
Geroldi D; Falcone C; Emanuele E
Curr Med Chem; 2006; 13(17):1971-8. PubMed ID: 16842191
[TBL] [Abstract][Full Text] [Related]
23. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S
Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336
[TBL] [Abstract][Full Text] [Related]
24. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.
Neviere R; Yu Y; Wang L; Tessier F; Boulanger E
Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623
[TBL] [Abstract][Full Text] [Related]
25. Advanced glycation end products and insulin resistance.
Unoki H; Yamagishi S
Curr Pharm Des; 2008; 14(10):987-9. PubMed ID: 18473850
[TBL] [Abstract][Full Text] [Related]
26. RAGE: a novel target for drug intervention in diabetic vascular disease.
Hudson BI; Schmidt AM
Pharm Res; 2004 Jul; 21(7):1079-86. PubMed ID: 15290845
[TBL] [Abstract][Full Text] [Related]
27. Advanced glycation endproducts: from precursors to RAGE: round and round we go.
Ramasamy R; Yan SF; Schmidt AM
Amino Acids; 2012 Apr; 42(4):1151-61. PubMed ID: 20957395
[TBL] [Abstract][Full Text] [Related]
28. Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System.
Yamagishi SI; Matsui T; Ishibashi Y; Isami F; Abe Y; Sakaguchi T; Higashimoto Y
Curr Pharm Des; 2017; 23(8):1135-1141. PubMed ID: 27774900
[TBL] [Abstract][Full Text] [Related]
29. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
Jandeleit-Dahm KA; Lassila M; Allen TJ
Ann N Y Acad Sci; 2005 Jun; 1043():759-66. PubMed ID: 16037303
[TBL] [Abstract][Full Text] [Related]
30. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.
Lindsey JB; Cipollone F; Abdullah SM; McGuire DK
Diab Vasc Dis Res; 2009 Jan; 6(1):7-14. PubMed ID: 19156622
[TBL] [Abstract][Full Text] [Related]
31. Understanding RAGE, the receptor for advanced glycation end products.
Bierhaus A; Humpert PM; Morcos M; Wendt T; Chavakis T; Arnold B; Stern DM; Nawroth PP
J Mol Med (Berl); 2005 Nov; 83(11):876-86. PubMed ID: 16133426
[TBL] [Abstract][Full Text] [Related]
32. The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome.
Guo WA; Knight PR; Raghavendran K
Intensive Care Med; 2012 Oct; 38(10):1588-98. PubMed ID: 22777515
[TBL] [Abstract][Full Text] [Related]
33. Receptor for advanced glycation end-products regulates lung fluid balance via protein kinase C-gp91(phox) signaling to epithelial sodium channels.
Downs CA; Kreiner LH; Johnson NM; Brown LA; Helms MN
Am J Respir Cell Mol Biol; 2015 Jan; 52(1):75-87. PubMed ID: 24978055
[TBL] [Abstract][Full Text] [Related]
34. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs.
Xue J; Ray R; Singer D; Böhme D; Burz DS; Rai V; Hoffmann R; Shekhtman A
Biochemistry; 2014 May; 53(20):3327-35. PubMed ID: 24824951
[TBL] [Abstract][Full Text] [Related]
35. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
36. The Development of Maillard Reaction, and Advanced Glycation End Product (AGE)-Receptor for AGE (RAGE) Signaling Inhibitors as Novel Therapeutic Strategies for Patients with AGE-Related Diseases.
Shen CY; Lu CH; Wu CH; Li KJ; Kuo YM; Hsieh SC; Yu CL
Molecules; 2020 Nov; 25(23):. PubMed ID: 33261212
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease.
Sasaki N; Toki S; Chowei H; Saito T; Nakano N; Hayashi Y; Takeuchi M; Makita Z
Brain Res; 2001 Jan; 888(2):256-262. PubMed ID: 11150482
[TBL] [Abstract][Full Text] [Related]
38. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders.
Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2007; 13(27):2832-6. PubMed ID: 17897026
[TBL] [Abstract][Full Text] [Related]
39. The AGE-RAGE pathway and its relation to cardiovascular disease in patients with chronic kidney disease.
Leurs P; Lindholm B
Arch Med Res; 2013 Nov; 44(8):601-10. PubMed ID: 24231387
[TBL] [Abstract][Full Text] [Related]
40. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications.
Ramasamy R; Yan SF; Schmidt AM
Ann N Y Acad Sci; 2011 Dec; 1243():88-102. PubMed ID: 22211895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
